Newron Pharmaceuticals SpA (NWRN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Novartis AG

Bachem Holding AG

Newron Pharmaceuticals SpA

Lonza Group AG

Idorsia Ltd.

Spexis Ltd.

ObsEva SA

Cosmo Pharmaceuticals NV

RELIEF THERAPEUTICS Holding SA

Why is Newron Pharmaceuticals SpA ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 231.49%

Poor long term growth as Net Sales has grown by an annual rate of 48.06% and Operating profit at 29.66% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

With ROE of 1624.07%, it has a Very Expensive valuation with a 190.40 Price to Book Value

Over the past year, while the stock has generated a return of 161.69%, its profits have risen by 236.2% ; the PEG ratio of the company is 0.1

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Newron Pharmaceuticals SpA for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Newron Pharmaceuticals SpA

159.48%

1.95

60.33%

Switzerland SMI

10.0%

0.63

15.85%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

48.06%

EBIT Growth (5y)

29.66%

EBIT to Interest (avg)

-2.46

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

27.41

Sales to Capital Employed (avg)

0.41

Tax Ratio

26.17%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

12.64%

ROE (avg)

231.49%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

190.40

EV to EBIT

8.72

EV to EBITDA

8.67

EV to Capital Employed

29.98

EV to Sales

5.13

PEG Ratio

0.05

Dividend Yield

ROCE (Latest)

343.88%

ROE (Latest)

1624.07%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Newron Pharmaceuticals SpA

Net Sales

At CHF 45.29 MM has Grown at 1,227.27%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely positive

Net Sales (CHF MM)

Pre-Tax Profit

At CHF 29.95 MM has Grown at 437.72%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CHF MM)

Net Profit

At CHF 24.59 MM has Grown at 376.88%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CHF MM)

Net Sales

Highest at CHF 45.29 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CHF MM)

Operating Profit

Highest at CHF 32.04 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CHF MM)

Operating Profit Margin

Highest at 70.76 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at CHF 29.95 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CHF MM)

Net Profit

Highest at CHF 24.59 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CHF MM)

EPS

Highest at CHF 1.2

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CHF)

Debtors Turnover Ratio

Highest at 1.98%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Newron Pharmaceuticals SpA

Debt-Equity Ratio

Highest at 2,787.59 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Cash and Eqv

Lowest at CHF 9.22 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents